LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "resistant aml" as a keyword



Inflammatory signaling pathways play a role in SYK inhibitor resistant AML

Sign Up to like & get
recommendations! Published in 2025 at "Scientific Reports"

DOI: 10.1038/s41598-025-96660-w

Abstract: Trials have shown promising clinical activity of the selective SYK inhibitor entospletinib in patients with high expressing HOXA9/MEIS1 acute leukemias. As the development of resistance mechanisms is a common problem in the use of targeted… read more here.

Keywords: inflammatory signaling; signaling pathways; inhibitor; resistant aml ... See more keywords

Hypoxia-Activated CBS/H2S Signaling Drives Drug Resistance in AML through CD36-Mediated Fatty Acid metabolism.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of leukocyte biology"

DOI: 10.1093/jleuko/qiaf065

Abstract: Hypoxia-associated H2S accumulation promotes chemotherapy resistance in solid tumor cells. This study delved into the mechanism by which CBS/H2S signaling is involved in the development of acute myeloid leukemia (AML) resistance to cytarabine (ara-C) under… read more here.

Keywords: cbs h2s; aml; resistant aml; ara resistant ... See more keywords

Maximal activation of apoptosis signaling by co-targeting anti-apoptotic proteins in BH3 mimetic-resistant AML and AML stem cells.

Sign Up to like & get
recommendations! Published in 2022 at "Molecular cancer therapeutics"

DOI: 10.1158/1535-7163.mct-21-0690

Abstract: MCL-1 is known to play a major role in resistance to BCL-2 inhibition, but the contribution of other BCL-2 family proteins has not been fully explored. We here demonstrate ineffectiveness of MCL-1 inhibitor AMG176 in… read more here.

Keywords: anti apoptotic; resistant aml; aml; resistance ... See more keywords

MCL1 Promotes Fatty Acid β-Oxidation in Therapy-Resistant AML through Cytoplasmic Sequestration of the Transcriptional Repressor IRF2BP2

Sign Up to like & get
recommendations! Published in 2024 at "Blood"

DOI: 10.1182/blood-2024-206516

Abstract: Despite extensive efforts aimed toward the development of improved molecular therapies targeting acute myeloid leukemia (AML), clinical outcomes remain poor. Notably, targeting BCL2 with venetoclax (Ven) in combination with azacitidine (Aza) has clinically delivered significant… read more here.

Keywords: irf2bp2; mcl1; ven aza; aza resistant ... See more keywords